Capnia,Inc, has announced that it has submitted an application to the FDA to request Orphan Drug Designation for its nasal technology that treats trigeminal neuralgia (TN).

Capnia’s therapeutic technology uses nasal, non-inhaled CO 2, delivered at a low-flow rate into the nasal cavity to alleviate symptoms of allergies as well as pain disorders related to the trigeminal nerve. ┬áThe use of Capnia’s nasal CO 2 product for the treatment of TN is supported by preclinical and clinical data demonstrating that CO 2 may inhibit sensory nerve activation, subsequent release of neuropeptides and alleviate trigeminally mediated pain. Collectively, these data suggest that nasal CO 2 may provide relief of symptoms associated with TN.